PT - JOURNAL ARTICLE AU - Benjamin Faucher AU - Rania Assab AU - Jonathan Roux AU - Daniel Levy-Bruhl AU - Cécile Tran Kiem AU - Simon Cauchemez AU - Laura Zanetti AU - Vittoria Colizza AU - Pierre-Yves Boëlle AU - Chiara Poletto TI - Reactive vaccination of workplaces and schools against COVID-19 AID - 10.1101/2021.07.26.21261133 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.26.21261133 4099 - http://medrxiv.org/content/early/2021/12/10/2021.07.26.21261133.short 4100 - http://medrxiv.org/content/early/2021/12/10/2021.07.26.21261133.full AB - As vaccination against COVID-19 stalls in some countries, increased accessibility and more adaptive approaches may be useful to keep the epidemic under control. Here, we study the impact of reactive vaccination targeting schools and workplaces where cases are detected, with an agent-based model accounting for COVID-19 natural history, vaccine characteristics, individuals’ demography and behaviour and social distancing. At an equal number of doses reactive vaccination produces a higher reduction in cases compared with non-reactive strategies, in the majority of scenarios. However, at high initial vaccination coverage or low incidence, few people are found to vaccinate around cases, thus the reactive strategy may be less effective than non-reactive strategies with moderate/high vaccination pace. In case of flare-ups, reactive vaccination could hinder spread if it is implemented quickly, is supported by enhanced test-trace-isolate and triggers an increased vaccine uptake. These results provide key information to plan an adaptive vaccination deployment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge financial support from Haute Autorité de Santé; the ANR and Fondation de France through the project NoCOV (00105995); the Municipality of Paris (https://www.paris.fr/) through the programme Emergence(s); EU H2020 grants MOOD (H2020-874850), and RECOVER (H2020-101003589); the ANRS through the project EMERGEN (ANRS0151); the ANR through the project SPHINX (ANR-17-CE36-0008-05); Institut des Sciences du Calcul et de la Donnée (ISCD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All relevant ethical guidelines have been followed.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode and input files of the study are posted on the github repository https://github.com/PYB-SU/ReactiveVaccination